US 11,834,497 B2
Glucose transporter 4 antibodies, methods of making the same, and uses thereof
David F. Tucker, Medford, MA (US); Kimberly-Anne Mattia, Plymouth Meeting, PA (US); Christine R. Fisher, Sommerville, MA (US); Benjamin J. Doranz, Philadelphia, PA (US); and Joseph B. Rucker, Philadelphia, PA (US)
Assigned to INTEGRAL MOLECULAR, INC., Philadelphia, PA (US)
Appl. No. 17/051,241
Filed by INTEGRAL MOLECULAR, INC., Philadelphia, PA (US)
PCT Filed Apr. 30, 2019, PCT No. PCT/US2019/029809
§ 371(c)(1), (2) Date Oct. 28, 2020,
PCT Pub. No. WO2019/213024, PCT Pub. Date Nov. 7, 2019.
Claims priority of provisional application 62/664,470, filed on Apr. 30, 2018.
Prior Publication US 2021/0238276 A1, Aug. 5, 2021
Int. Cl. C07K 16/28 (2006.01); A61P 3/10 (2006.01); C07K 14/705 (2006.01); G01N 33/68 (2006.01)
CPC C07K 16/28 (2013.01) [A61P 3/10 (2018.01); C07K 14/705 (2013.01); G01N 33/6893 (2013.01); C07K 2317/565 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01)] 10 Claims
 
1. An antibody, or antigen binding fragment thereof, that binds to a GLUT4 protein, wherein the antibody, or antigen binding fragment thereof, comprises a light chain variable (VL) region comprising a light chain CDR1 (LCDR1), a light chain CDR2 (LCDR2), and a light chain CDR3 (LCDR3), and a heavy chain variable (VH) region comprising a heavy chain CDR1 (HCDR1), a heavy chain CDR2 (HCDR2), and a heavy chain CDR3 (HCDR3), wherein:
(i) the LCDR1 has the amino acid sequence of SEQ ID NO: 42; the LCDR2 has the amino acid sequence of SEQ ID NO: 43; the LCDR3 has the amino acid sequence of SEQ ID NO: 44; the HCDR1 has the amino acid sequence of SEQ ID NO: 45; the HCDR2 has the amino acid sequence of SEQ ID NO: 46; and the HCDR3 has the amino acid sequence of SEQ ID NO: 47;
(ii) the LCDR1 has the amino acid sequence of SEQ ID NO: 18; the LCDR2 has the amino acid sequence of SEQ ID NO: 19; the LCDR3 has the amino acid sequence of SEQ ID NO: 20; the HCDR1 has the amino acid sequence of SEQ ID NO: 21; the HCDR2 has the amino acid sequence of SEQ ID NO: 22; and the HCDR3 has the amino acid sequence of SEQ ID NO: 23;
(iii) the LCDR1 has the amino acid sequence of SEQ ID NO: 24; the LCDR2 has the amino acid sequence of SEQ ID NO: 25; the LCDR3 has the amino acid sequence of SEQ ID NO: 26; the HCDR1 has the amino acid sequence of SEQ ID NO: 27; the HCDR2 has the amino acid sequence of SEQ ID NO: 28; and the HCDR3 has the amino acid sequence of SEQ ID NO: 29;
(iv) the LCDR1 has the amino acid sequence of SEQ ID NO: 60; the LCDR2 has the amino acid sequence of SEQ ID NO: 61; the LCDR3 has the amino acid sequence of SEQ ID NO: 62; the HCDR1 has the amino acid sequence of SEQ ID NO: 63; the HCDR2 has the amino acid sequence of SEQ ID NO: 64; and the HCDR3 has the amino acid sequence of SEQ ID NO: 65; or
(v) the LCDR1 has the amino acid sequence of SEQ ID NO: 78; the LCDR2 has the amino acid sequence of SEQ ID NO: 79; the LCDR3 has the amino acid sequence of SEQ ID NO: 80; the HCDR1 has the amino acid sequence of SEQ ID NO: 81; the HCDR2 has the amino acid sequence of SEQ ID NO: 82; and the HCDR3 has the amino acid sequence of SEQ ID NO: 83.